Celltrion, Teva deal

Celltrion granted Teva exclusive rights to commercialize biosimilars CT-P10 and CT-P6 in the U.S. and Canada. Celltrion will receive $160 million up front, of which $60 million is refundable or creditable depending on undisclosed milestones. Celltrion will be responsible for completing all clinical development and regulatory activities. The companies will share profits. ...